Market Access

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses breakout session and the impact of healthcare policies on manufacturing and commercialization.

The conference’s opening keynote sets the scene for 2025 and the years to come.

When it comes to navigating the complex clinical and commercial landscape for specialty drugs—including hurdles in access to these critical but costly therapies—today’s specialty pharmacies are bringing more skills and services to the table.

As the dust settles on the first round of Medicare negotiations, not everything is what it seems.

Why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation.

Despite support from patient assistance programs and legislation designed to combat growing healthcare costs, challenges remain.

A cross-sectional study investigates changes in Medicare Advantage enrollment among Medicare beneficiaries with end-stage renal disease in the first two years of the Act.

This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization.

How can industry stakeholders ensure the quality and supply chain security of existing product?

The new vials of Zepbound are available through a new self-pay pharmacy channel, priced over 50% lower than other incretin medications for obesity.

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

A lack of access could shut out patients in need of maintenance drugs for complex conditions.

What does the legislation mean for patient access leaders, pharma brand managers, and patient service owners? Industry experts weigh in.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Balancing innovation focus with optimized decision-making.

Investigators evaluate differences in end-of-life care between Medicare beneficiaries in Medicare Advantage vs. traditional Medicare.

How teamwork among safety-net healthcare providers and pharma can make the difference.

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

The impact of income-based price controls in healthcare.

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.

A difference-in-differences analysis explores the correlation between direct-acting antiviral prescriptions for hepatitis C virus and the softening of state-level limitations.